Telemedicine follow-up after hospital discharge for COPD exacerbation was significantly more effective than standard care and received high patient satisfaction scores.
Astegolimab did result in a statistically significant reduction of annualized exacerbation rates in a similar phase 2b trial, but the result was not replicated in phase 3.
Itepekimab performed well in the phase 3 AERIFY-1 trial but fell short of anticipated outcomes in AERIFY-2, prompting further analysis after the mixed results.